Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Millepachine is a **natural chalcone compound** derived from *Millettia pachycarpa* Benth, exhibiting **antitumor activity primarily via inhibition of topoisomerase II and tubulin polymerization**.[1][2] It operates through dual mechanisms: (1) it **irreversibly inhibits the colchicine-binding site of β-tubulin**, disrupting microtubule assembly and inducing G2/M cell cycle arrest; (2) it **inhibits topoisomerase II**, stabilizing the topoisomerase II-DNA cleavable complex, causing DNA double-strand breaks and apoptosis in tumor cells. Millepachine has demonstrated activity against multiple cancer cell lines, including ovarian and hepatocellular carcinoma, and can overcome multidrug resistance in in vitro models.[1][2][3][4] Importantly, **NF-κB pathway activation** occurs following DNA damage induced by millepachine, contributing to pro-apoptotic effects in tumor cells.[1] Amino acid prodrugs and other derivatives of millepachine have been synthesized to enhance its solubility and antitumor potency.[3][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on millepachine.